NCT00822757View on ClinicalTrials.gov

Safety and Immunogenicity Study of V710 Lyophilized Formulation (V710-004)

PHASE1CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

October 31, 2007

Study Completion Date

December 31, 2007

Conditions
Healthy
Interventions
BIOLOGICAL

Comparator: V710

Single dose V710 (60 Mcg/0.5 mL) by intramuscular injection.

BIOLOGICAL

Comparator: placebo

Single dose of buffered saline placebo (0.5 mL) by intramuscular injection.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00822757 - Safety and Immunogenicity Study of V710 Lyophilized Formulation (V710-004) | Biotech Hunter | Biotech Hunter